Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.

Fomivirsen

Подписчиков: 0, рейтинг: 0
Fomivirsen
Fomivirsen composite.png
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
Pregnancy
category
  • AU: B2
Routes of
administration
Intravitreal injection
ATC code
Legal status
Legal status
  • Withdrawn
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C204H263N63O114P20S20
Molar mass 6682.35 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Fomivirsen (brand name Vitravene) is an antisense antiviral drug that was used in the treatment of cytomegalovirus retinitis (CMV) in immunocompromised patients, including those with AIDS. It was administered via intraocular injection.

It was discovered at the NIH and was licensed and initially developed by Isis Pharmaceuticals, which subsequently licensed it to Novartis. It was licensed by the FDA for CMV in Aug 1998, and was the first antisense drug that was approved.

Novartis withdrew the marketing authorization in the EU in 2002 and in the US in 2006. The drug was withdrawn because while there was a high unmet need for drugs to treat CMV when the drug was initially discovered and developed due to the CMV arising in people with AIDS, the development of HAART dramatically reduced the number of cases of CMV.

It is an antisense oligonucleotide -- a synthetic 21 member oligonucleotide with phosphorothioate linkages (which are resistant to degradation by nucleases) and has the sequence:

  • 5'-GCG TTT GCT CTT CTT CTT GCG-3'

It blocks translation of viral mRNA by binding to the complementary sequence of the mRNA transcribed from the template segment of a key CMV gene UL123, which encodes the CMV protein IE2. It was the first antisense antiviral approved by the FDA.

Further reading

  • Grillone LR, Lanz R (April 2001). "Fomivirsen". Drugs of Today. 37 (4): 245–255. doi:10.1358/dot.2001.37.4.620590. PMID 12768225.
  • Geary RS, Henry SP, Grillone LR (2002). "Fomivirsen: clinical pharmacology and potential drug interactions". Clinical Pharmacokinetics. 41 (4): 255–60. doi:10.2165/00003088-200241040-00002. PMID 11978144.
  • Vitravene Study Group (April 2002). "Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS". American Journal of Ophthalmology. 133 (4): 475–83. doi:10.1016/S0002-9394(02)01326-0. PMID 11931781.
  • Roehr B (October 1998). "Fomivirsen approved for CMV retinitis". Journal of the International Association of Physicians in AIDS Care. 4 (10): 14–6. PMID 11365956.

External links


Новое сообщение